Guillain-Barré syndrome following ChAdOx1-S/nCoV-19 vaccine

Guillain-Barré syndrome variant occurring after SARS-CoV-2 vaccination

Skeletal Muscle and Peripheral Nerve Histopathology in COVID-19

Encephalopathies Associated With Severe COVID-19 Present Neurovascular Unit Alterations Without Evidence for Strong Neuroinflammation

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals

Naturally acquired SARS-CoV-2 immunity persists for up to 11 months following infection

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

The incubation period distribution of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Increased transmissibility and global spread of SARSCoV-2 variants of concern as at June 2021

Two reports on Clinical Fellowships that took place in 2020